Risperdal Litigation Prepares for Upcoming Status Conference in December, Bernstein Liebhard LLP Reports

Share Article

The Firm is representing numerous plaintiffs who have filed Risperdal gynecomastia lawsuits in the Philadelphia Court of Common Pleas.

Free Case Review
As our Firm has already filed several Risperdal gynecomastia lawsuits in this Pennsylvania litigation, we are looking forward to its December status conference.

A consolidated litigation that now includes some 950 Risperdal lawsuits (http://www.risperdallawsuit2014.com/) is preparing for a status conference scheduled for the first week in December, Bernstein Liebhard LLP reports.

A Calendar posted by the Philadelphia Court of Common Pleas lists a conference scheduled for December 2nd at 2:00 p.m., at which time parties will discuss matters related to cases filed against the antipsychotic medication’s manufacturers, Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals. Plaintiffs in these cases allege Risperdal’s association with a number of complications, including gynecomastia, a condition referring to male breast growth that may result in mastectomy or liposuction procedures to remove excess breast tissue that may have developed because of the medication. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

“As our Firm has already filed several Risperdal gynecomastia lawsuits in this Pennsylvania litigation, we are looking forward to its December status conference,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including Risperdal. The attorneys at Bernstein Liebhard LLP are currently offering free and confidential case evaluations to men and young boys who allegedly sustained Risperdal gynecomastia complications, and may now be eligible to file a lawsuit.

Risperdal Lawsuits

As of November 2014, at least 945 Risperdal case records were included in the consolidated antipsychotic drug litigation in Pennsylvania, after being filed by individuals who allege gynecomastia and other complications. Among other things, plaintiffs in these cases accuse Johnson & Johnson and Janssen of concealing the link between Risperdal and gynecomastia, and promoting it for certain pediatric uses not approved by the U.S. Food and Drug Administration (FDA).

Risperdal is cleared in the U.S. to treat adult and adolescent schizophrenia, bipolar disorder in adults and children between the ages of 10 and 17, as well as irritability in children ages 5-to-16 years old with autistic disorder.* The drug is also frequently prescribed off label to treat symptoms associated with ADHD, according to research.**

Aside from the numerous product liability lawsuits that accuse Risperdal’s manufacturers of promoting the drug for off-label uses, the federal government has made similar claims against Johnson & Johnson and Janssen as well. In November 2013, a $2.2 billion settlement was reached between the companies and the U.S. Department of Justice that resolved charges involving the companies’ alleged concealment of gynecomastia and other side effects of the drug. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Alleged victims of Risperdal and gynecomastia may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. Learn more about the alleged association between Risperdal and gynecomastia when you visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

*health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
**http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, Risperdal Prescribing Information, FDA, 2009

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website